Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q1 EPS by 11c; raises guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- S&P 500, Nasdaq climb as AI-linked stocks recover ahead of earnings
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Oil slips from five-month highs with Hormuz crossings, Russian sanctions waiver in focus
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
Tweet
Share
E-mailGet Alerts KNSA Hot Sheet
Join SI Premium – FREE
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q1 EPS of ($0.25), $0.11 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $79.86 million versus the consensus estimate of $76.97 million.
GUIDANCE:
Kiniksa Pharmaceuticals, Ltd. sees FY2024 revenue of $370-390 million, versus the consensus of $383 million.
For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Top Fintech and Crypto Stocks: Moness Crespi Hardt’s Picks
- SK hynix shares jump on Nvidia memory partnership report
- NiSource (NI) PT Raised to $48 at BMO Capital
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
